News Allon Therapeutics Inc.

Equities

NPCUF

CA0197741089

Market Closed - OTC Markets Other stock markets 12:16:36 26/03/2024 am IST			5-day change	1st Jan Change
0.0001 ^USD	+9,900.00%		-.--%	+9,900.00%

2013	Paladin Labs Inc. completed the acquisition of substantially all assets from Allon Therapeutics, Inc..	CI
2013	Paladin Labs Inc. signed a non-binding term sheet to acquire substantially all assets from Allon Therapeutics, Inc. for CAD 0.9 million.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Paladin Labs Inc. completed the acquisition of substantially all assets from Allon Therapeutics, Inc..	16/13/16	CI
Paladin Labs Inc. signed a non-binding term sheet to acquire substantially all assets from Allon Therapeutics, Inc. for CAD 0.9 million.	30/13/30	CI
Allon Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2013	30/13/30	CI
Allon Therapeutics, Inc. Reports Earnings Results for the Year Ended December 31, 2012	28/13/28	CI
Allon Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	28/13/28	CI
Allon Updates On Strategic Review Process	05/13/05	CI
Michael Aldridge Resigns as Director of Allon Therapeutics, Inc	31/13/31	CI
Allon Therapeutics, Inc. Implements Staff and Administrative Reductions; Announces Resignation of Michael Gold as Vice President, Clinical Development and Chief Medical Officer	22/12/22	CI
Allon Therapeutics, Inc. Announces PSP Clinical Trial Results; Announces to Reduce Staff	19/12/19	CI
The United States, New Zealand & Mexico Issue Patent for New Allon Therapeutics, Inc. Platform	05/12/05	CI
Allon Therapeutics, Inc. Completes Patient Treatment in Pivotal Trial Evaluating Allon's Davunetide	13/12/13	CI
Allon Therapeutics, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2012	06/12/06	CI
Allon Therapeutics, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2012	08/12/08	CI
Allon Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2012	09/12/09	CI
Allon Therapeutics, Inc. announced that it expects to receive CAD 10 million in funding from NDI Capital and other investors.	16/12/16	CI
Allon Therapeutics, Inc. Receives U.S. Patent for Neurotoxicity Technology Platform in the Treatment of Peripheral Neuropathy	28/12/28	CI
Allon Therapeutics, Inc. Advances Parkinson's Disease Program	13/12/13	CI
Allon Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	10/12/10	CI
Allon Therapeutics, Inc. Reports Audited Earnings Results for the Year Ended December 31, 2011	10/12/10	CI
Allon Therapeutics, Inc. announced that it has receive CAD 2.5 million in funding from NDI Capital.	09/12/09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Allon Therapeutics Inc.

Equities

NPCUF

CA0197741089

Summary

Filters